Navigation Links
Key molecule suppresses growth of cancerous liver tumors, Mayo study finds
Date:2/13/2013

ROCHESTER, Minn. -- A molecule already implicated in a number of diverse cellular functions can suppress the growth of tumors in the liver, a Mayo Clinic Cancer Center study has found. Its name is IQGAP1, and when the molecule is active in the cells that surround a tumor cell, this "tumor microenvironment" becomes less hospitable to cancer growth. When the molecule is deficient, cancer thrives.

Results of the study appear in the Journal of Clinical Investigation. The findings give new insight into cancer metastasis, the ability of a tumor to spread from its primary site to distant organs such as the brain, lung or liver. The results also point to new targets for preventing or treating liver metastases, the major cause of death from cancer.

"Tumor cells are intelligent -- they talk to the cells in their surroundings to change the way they behave and make the environment supportive of cancer growth. If we can disrupt the communication between the tumor cells and the tumor microenvironment, we can prevent tumor growth or metastasis in the liver," says senior study author Ningling Kang, Ph.D., a biochemist and molecular biologist at Mayo Clinic.

For certain solid tumors, about 70 to 90 percent of the tumor mass is made up of microenvironment -- a complex mix of noncancerous cells, secreted extracellular matrix proteins, and tumor-promoting signaling molecules. This tumor microenvironment supports tumor growth and drug resistance. Mechanisms regulating the tumor microenvironment are not well understood.

IQGAP1 controls the shape and movement of cells. To study the effects of this molecule on liver metastases, Dr. Kang and her colleagues implanted tumor cells into the livers of mice genetically engineered to lack the molecule.

The implanted tumor cells still had the molecule, but the cells that made up the tumor microenvironment did not. When researchers compared the progression of cancer between mutant and normal mice, they found that mice without the molecule developed more liver metastases. They also followed up these studies in mice by comparing samples of normal and cancerous liver tissues of colorectal cancer patients. They discovered that the levels of IQGAP1 were reduced in the tumor microenvironment of liver metastases than in the normal tissue, suggesting that the tumor somehow communicates with its surroundings to tamp down the activity of this critical molecule.

This communication went both ways. Through a number of basic functional experiments, Dr. Kang and her colleagues showed that IQGAP1 interacts with and suppresses a powerful signaling molecule called TGF-beta receptor that tells normal cells that surround a tumor cell to become tumor-promoting cells.

"We think that tumor cells come into the liver and give orders to the signaling molecules in the surrounding normal cells to reduce the amount of IQGAP1, thereby creating a good tumor microenvironment for themselves," Dr. Kang says. "If we can understand exactly how they do this, then we may be able to uncover new therapeutic targets for liver metastasis."


'/>"/>
Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
2. Beta-catenin molecule is required for tooth root formation
3. Mayo Clinic researchers find new molecule to target in pancreatic cancer treatment
4. CWRU School of Medicine researchers discover new molecule linked to late-stage breast cancer
5. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
6. Looking for the anti-Alzheimers molecule -- A new approach to treating a devastating disease
7. Fat molecule ceramide may factor in muscle loss in older adults
8. New developments reveal a molecule with a promising function in terms of cancer treatment.
9. Measuring molecules with the naked eye
10. Molecule shows effectiveness against drug-resistant myeloma
11. Molecule found that inhibits recovery from stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... ANN ARBOR, Mich. (PRWEB) , ... ... ... Global Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing ... the dietary supplement industry. The organization, which plans to publish the first ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... oral braces. "The rubber bands used in conjunction with my braces always rubbed ... to design a way to prevent this problem." The O.B.S. was the result ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly ... assembly protocols involve many repetitive steps and often scientists require many different versions ... high-throughput needed, and results in a lower error rate and cost saving for ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Novartis announced today ... has accepted the company,s Biologics License Application (BLA) ... an investigational chimeric antigen receptor T cell (CAR-T) ... young adult patients with B-cell acute lymphoblastic leukemia ... Novartis for a CAR-T. The priority review designation ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
(Date:3/29/2017)... 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical technology ... medical devices for pain management, stroke rehabilitation, cardiac monitoring ... the Company,s 2016 full-year investor webcast on Monday, April 3, ... The Company expects to file its 2016 full year ... ...
Breaking Medicine Technology: